Stock Track | Twist Bioscience Soars Over 5% Pre-Market on Q1 Earnings Beat, Upbeat Q2 Guidance

Stock Track

02-03

Shares of Twist Bioscience Corp (TWST) surged over 5% in pre-market trading on Monday, following the company's better-than-expected fiscal first-quarter 2025 earnings results and an optimistic revenue outlook for the current quarter. The stock rally reflects investors' positive sentiment toward the synthetic biology and genomics company's strong performance and growth prospects.

For the quarter ended December 31, 2024, Twist Bioscience reported a net loss of $0.53 per share, narrower than analysts' consensus estimate of a $0.62 loss per share. Revenue came in at $88.7 million, surpassing the FactSet consensus of $87 million.

Looking ahead, the company guided for fiscal second-quarter 2025 revenue in the range of $91 million to $93 million, exceeding Wall Street's expectations of $90.9 million. This upbeat guidance underscores Twist Bioscience's confidence in sustaining its growth momentum amid rising demand for its synthetic DNA-based products and services.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1167387808"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167387808\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1167387808?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-03 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167387808","market":"hk","top_or_hot":-1,"title":"Stock Track | Twist Bioscience Soars Over 5% Pre-Market on Q1 Earnings Beat, Upbeat Q2 Guidance","media":"Stock Track","content":"<html><body><p>Shares of Twist Bioscience Corp (TWST) surged over 5% in pre-market trading on Monday, following the company's better-than-expected fiscal first-quarter 2025 earnings results and an optimistic revenue outlook for the current quarter. The stock rally reflects investors' positive sentiment toward the synthetic biology and genomics company's strong performance and growth prospects.</p>\n<p>For the quarter ended December 31, 2024, Twist Bioscience reported a net loss of $0.53 per share, narrower than analysts' consensus estimate of a $0.62 loss per share. Revenue came in at $88.7 million, surpassing the FactSet consensus of $87 million.</p>\n<p>Looking ahead, the company guided for fiscal second-quarter 2025 revenue in the range of $91 million to $93 million, exceeding Wall Street's expectations of $90.9 million. This upbeat guidance underscores Twist Bioscience's confidence in sustaining its growth momentum amid rising demand for its synthetic DNA-based products and services.</p></body></html>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Stock Track | Twist Bioscience Soars Over 5% Pre-Market on Q1 Earnings Beat, Upbeat Q2 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Twist Bioscience Soars Over 5% Pre-Market on Q1 Earnings Beat, Upbeat Q2 Guidance\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-03 20:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Twist Bioscience Corp (TWST) surged over 5% in pre-market trading on Monday, following the company's better-than-expected fiscal first-quarter 2025 earnings results and an optimistic revenue outlook for the current quarter. The stock rally reflects investors' positive sentiment toward the synthetic biology and genomics company's strong performance and growth prospects.</p>\n<p>For the quarter ended December 31, 2024, Twist Bioscience reported a net loss of $0.53 per share, narrower than analysts' consensus estimate of a $0.62 loss per share. Revenue came in at $88.7 million, surpassing the FactSet consensus of $87 million.</p>\n<p>Looking ahead, the company guided for fiscal second-quarter 2025 revenue in the range of $91 million to $93 million, exceeding Wall Street's expectations of $90.9 million. This upbeat guidance underscores Twist Bioscience's confidence in sustaining its growth momentum amid rising demand for its synthetic DNA-based products and services.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"","article_id":"1167387808","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167387808","pubTimestamp":1738585734,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Twist Bioscience Corp  surged over 5% in pre-market trading on Monday, following the company's better-than-expected fiscal first-quarter 2025 earnings results and an optimistic revenue outlook for the current quarter. The stock rally reflects investors' positive sentiment toward the synthetic biology and genomics company's strong performance and growth prospects.For the quarter ended December 31, 2024, Twist Bioscience reported a net loss of $0.53 per share, narrower than analysts' con","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"股票赛道Twist Bioscience因第一季度盈利超出预期和乐观的第二季度指引而盘前飙升超过5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"Shares of Twist Bioscience Corp (TWST) surged over 5% in pre-market trading on Monday, following the company's better-than-expected fiscal first-quarter 2025 earnings results and an optimistic revenue outlook for the current quarter. The stock rally reflects investors' positive sentiment toward the synthetic biology and genomics company's strong performance and growth prospects.\nFor the quarter ended December 31, 2024, Twist Bioscience reported a net loss of $0.53 per share, narrower than analysts' consensus estimate of a $0.62 loss per share. Revenue came in at $88.7 million, surpassing the FactSet consensus of $87 million.\nLooking ahead, the company guided for fiscal second-quarter 2025 revenue in the range of $91 million to $93 million, exceeding Wall Street's expectations of $90.9 million. This upbeat guidance underscores Twist Bioscience's confidence in sustaining its growth momentum amid rising demand for its synthetic DNA-based products and services.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}